The abstract is read at the publisher; the summary is JClub's.
TriPRIL, an APRIL-based dual-target CAR T-cell therapy for relapsed or refractory multiple myeloma, showed no dose-limiting toxicities at 1×10^8 or 3×10^8 cells in 15 infused patients.
- Why it matters: BCMA loss is linked to relapse after BCMA-directed CAR T-cell therapy, and single-antigen targeting risks antigen escape. Dual targeting of BCMA and TACI via their shared ligand APRIL aims to help sustain responses.
- What they did: In this open-label phase 1 dose-escalation and expansion trial at Massachusetts General Hospital, 15 infused patients received cyclophosphamide/fludarabine lymphodepletion followed by TriPRIL at 1×10^8 or 3×10^8 CAR T cells, with safety as the primary endpoint.
- The result: Most adverse events were neutropenia (93%) and nausea (80%), with grade 3 or worse non-haematological events in 33% and only grade 1–2 cytokine release syndrome in 87%. The recommended phase 2 dose was 3×10^8 cells, with no treatment-related deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.